Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 17, 2026, reports a significant regulatory milestone. The European Commission has approved Exdensur (depemokimab), an ultra-long-acting biologic, for two indications: severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). This approval positions Exdensur as the first and only ultra-long-acting biologic in the EU for these respiratory diseases, offering a twice-yearly dosing regimen.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory announcement regarding product approval rather than a financial results report.
Material Changes and Clinical Data
The primary material change is the expansion of GSK's commercial footprint in the EU with the approval of Exdensur. The approval is supported by robust Phase III clinical data:
- Severe Asthma (SWIFT Trials): Depemokimab demonstrated a 58% reduction (SWIFT-1) and 48% reduction (SWIFT-2) in annualized asthma exacerbation rates compared to placebo. A pooled analysis showed a 72% reduction in clinically significant exacerbations requiring hospitalization or emergency department visits.
- CRSwNP (ANCHOR Trials): Treatment resulted in statistically significant improvements in nasal polyp scores and nasal obstruction verbal response scales at 52 weeks.
- Safety Profile: The drug was well-tolerated across trials, with side effect rates and severity similar to placebo.
Outlook, Management Commentary, and Risks
Management Commentary: Kaivan Khavandi, SVP of Global Head, Respiratory, Immunology & Inflammation R&D, stated that Exdensur offers an innovative option with sustained efficacy over six months, potentially redefining care for millions of patients. The twice-yearly dosing addresses unmet needs for patients with persistent symptoms.
Pipeline and Outlook: GSK is continuing to evaluate depemokimab in Phase III trials for other conditions, including eosinophilic granulomatosis with polyangiitis (EGPA), hyper eosinophilic syndrome (HES), and COPD (ENDURA-1, ENDURA-2, and VIGILANT trials).
Risks: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's Annual Report on Form 20-F for 2024 and Q4 Results for 2025, including regulatory, competitive, and commercialization uncertainties.
Key Facts for Investor Verification
- Verify the commercial launch timeline and pricing strategy for Exdensur in the EU market.
- Monitor the progress of ongoing Phase III trials for COPD (ENDURA/VIGILANT) and rare diseases (OCEAN/DESTINY) to assess future revenue potential.
- Review the competitive landscape for IL-5 inhibitors in the EU to understand market share dynamics.
- Confirm the impact of this approval on GSK's overall respiratory portfolio revenue in upcoming quarterly reports.